European Journal of Clinical Pharmacology

, Volume 62, Issue 10, pp 781–792 | Cite as

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

  • D. J. Leeming
  • P. Alexandersen
  • M. A. Karsdal
  • P. Qvist
  • S. Schaller
  • L. B. Tankó
Review Article



Maintenance of the structural and functional integrity of the skeleton is a critical function of a continuous remodeling driven by highly associated processes of bone resorption and synthetic activities driven by osteoclasts and osteoblasts, respectively. Acceleration of bone turnover, accompanied with a disruption of the coupling between these cellular activities, plays an established role in the pathogenesis of metabolic bone diseases, such as osteoporosis. During the past decades, major efforts have been dedicated to the development and clinical assessment of biochemical markers that can reflect the rate of bone turnover. Numerous studies have provided evidence that serum levels or urinary excretion of these biomarkers correlate with the rate of bone loss and fracture risk, proving them as useful tools for improving identification of high-risk patients.


The aim of the present review is to give an update on biomarkers of bone turnover and give an overview of their applications in epidemiological and clinical research.


Special attention is given to their utility in clinical trials testing the efficacy of drugs for the treatment of osteoporosis and how they supplement bone mass measurements. Recent evidence suggests that biochemical markers may provide information on bone age that may have indirectly relates to bone quality; the latter is receiving increasing attention. A more targeted use of biomarkers could further optimize identification of high-risk patients, the process of drug discovery, and monitoring of the efficacy of osteoporosis treatment in clinical settings.


Bone resorption markers Bone formation markers Bone regulatory proteins Bone mineral density Fracture risk Treatment Monitoring Postmenopausal women 


  1. 1.
    Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD (2004) Efficacy and safety of ibandronate given by intravenous injection one every 3 months. Bone 34:881–889PubMedCrossRefGoogle Scholar
  2. 2.
    Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890PubMedCrossRefGoogle Scholar
  3. 3.
    Amin S (2003) Male osteoporosis: epidemiology and pathophysiology. Curr Osteoporos Rep 1:71–77PubMedGoogle Scholar
  4. 4.
    Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735PubMedCrossRefGoogle Scholar
  5. 5.
    Baron R (2003) Anatomy and Biology of Bone Matrix and cellular Elements. Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 1–8Google Scholar
  6. 6.
    Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404–1410PubMedCrossRefGoogle Scholar
  7. 7.
    Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C (1996) Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 81:2419–2422PubMedCrossRefGoogle Scholar
  8. 8.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  9. 9.
    Bone HG (1992) The future of osteoporosis diagnosis and therapy. Ann Ital Med Int 7(3 Suppl):166S–170SPubMedGoogle Scholar
  10. 10.
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  11. 11.
    Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, Richy F, Reginster JY (2003) Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44:259–265PubMedCrossRefGoogle Scholar
  12. 12.
    Byrjalsen I, Cloos PA, Qvist P, Christiansen C (2004) The degree of isomerization of collagen type I C-telopeptide in postmenopausal women: A potential biochemical index of bone quality. J Bone Miner Res 19(suppl 1):S375Google Scholar
  13. 13.
    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738PubMedCrossRefGoogle Scholar
  14. 14.
    Chailurkit L, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R (2003) Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal women. J Bone Miner Metab 21:421–427PubMedCrossRefGoogle Scholar
  15. 15.
    Chao T, Yu J, Ku C, Chen MM, Lee SH, Janckila AJ, Yam LT (2005) Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 544:544–550Google Scholar
  16. 16.
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD (2000) Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27:283–286PubMedCrossRefGoogle Scholar
  17. 17.
    Chen CJ, Chao TY, Chu DM, Janckila AJ, Cheng SN (2004) Osteoblast and osteoclast activity in a malignant infantile osteopetrosis patient following bone marrow transplantation. J Pediatr Hematol Oncol 26:5–8PubMedCrossRefGoogle Scholar
  18. 18.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRefGoogle Scholar
  19. 19.
    Chesnut CH 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ (1997) Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29–37PubMedCrossRefGoogle Scholar
  20. 20.
    Chesnut CH, III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276PubMedCrossRefGoogle Scholar
  21. 21.
    Chesnut CH III (2001) Sources of biological bone marker variation. In Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: Biochemical and clinical perspectives. Martin Dunitz, London, pp 119–121Google Scholar
  22. 22.
    Christgau S, Bitsch-Jensen O, Hanover BN, Gamwell HE, Qvist P, Alexandersen P, Bang HD (2000) Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511PubMedCrossRefGoogle Scholar
  23. 23.
    Cloos PAC, Lyubimova N, Solberg H, Qvist P, Christiansen C, Byrjalsen I, Christgau S (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50:279–289PubMedGoogle Scholar
  24. 24.
    Consensus Development Conference V (1993) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 90:646–650Google Scholar
  25. 25.
    Cooper C, Barrett-Connor E (1996) Epidemiology of osteoporosis. Osteoporosis (1996). Proceedings of the 1996 world congress on osteoporosis. Amsterdam, The Netherlands, 18–23 May, 1996. Eds. Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD. Elservier, 75–86Google Scholar
  26. 26.
    Crane M, Davis T, Kaldate R, Black C, Davies R, Devas V, Williams W (2005) Relating increases in bone mineral density and fracture risk reduction with early suppression in biomarkers of bone turnover: a literature-based meta-analysis of bisphosphonate treatments. J Bone Miner Res 20(suppl 1):S95Google Scholar
  27. 27.
    Delmas PD (1993) Biochemical markers of bone turnover. J Bone Miner Res 8(Suppl 2):S549–S555PubMedGoogle Scholar
  28. 28.
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17PubMedCrossRefGoogle Scholar
  29. 29.
    Delmas PD, Pornel B, Felsenberg D, Stakkestad JA, Radowicki S, Garnero P, Hardy P, Dain MP, Petitier B (2001) Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. Am J Obstet Gynecol 184:32–40PubMedCrossRefGoogle Scholar
  30. 30.
    Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599–604PubMedCrossRefGoogle Scholar
  31. 31.
    Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride, J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798PubMedCrossRefGoogle Scholar
  32. 32.
    Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME (2000) Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85:1783–1788PubMedCrossRefGoogle Scholar
  33. 33.
    Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741–748PubMedCrossRefGoogle Scholar
  34. 34.
    Epstein S (2005) The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80:379–388PubMedCrossRefGoogle Scholar
  35. 35.
    Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRefGoogle Scholar
  36. 36.
    Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272:9755–9763PubMedCrossRefGoogle Scholar
  37. 37.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700PubMedCrossRefGoogle Scholar
  38. 38.
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedGoogle Scholar
  39. 39.
    Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD (1998) Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563–569PubMedCrossRefGoogle Scholar
  40. 40.
    Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. Bone Miner Res 14:1614–1621CrossRefGoogle Scholar
  41. 41.
    Garnero P, Darte C, Delmas PD (1999) A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24:603–609PubMedCrossRefGoogle Scholar
  42. 42.
    Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867PubMedCrossRefGoogle Scholar
  43. 43.
    Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4:50–63PubMedGoogle Scholar
  44. 44.
    Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Vaananen HK, Akesson K, Obrant KJ (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386–393PubMedCrossRefGoogle Scholar
  45. 45.
    Grados F, Brazier M, Kamel S, Mathieu M, Hurtebize N, Maamer M, Garabedian M, Sebert JL, Fardellone P (2003) Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 88:5175–5179PubMedCrossRefGoogle Scholar
  46. 46.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438PubMedCrossRefGoogle Scholar
  47. 47.
    Goemaere S, Van Pottelbergh I, Zmierczak H, Toye K, Daems M, Demuynck R, Myny H, De Bacquer D, Kaufman JM (2001) Inverse association between bone turnover rate and bone mineral density in community-dwelling men <70 years of age: no major role of sex steroid status. Bone 29:286-91Google Scholar
  48. 48.
    Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251–1258PubMedGoogle Scholar
  49. 49.
    Heaney RP (2003) Is the paradigm shifting? Bone 33:457–465PubMedCrossRefGoogle Scholar
  50. 50.
    Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ (2004) Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34:140–147PubMedCrossRefGoogle Scholar
  51. 51.
    Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253PubMedCrossRefGoogle Scholar
  52. 52.
    Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–275PubMedGoogle Scholar
  53. 53.
    Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? Lab Clin Med 146:13–17CrossRefGoogle Scholar
  54. 54.
    Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9–18PubMedCrossRefGoogle Scholar
  55. 55.
    Joffe P, Heaf JG, Hyldstrup L (1994) Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD. Kidney Int 46:838–846PubMedGoogle Scholar
  56. 56.
    Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ, III, O’neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  57. 57.
    Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard A, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476PubMedGoogle Scholar
  58. 58.
    Keen RW, Nguyen T, Sobnack R, Perry LA, Thompson PW, Spector TD (1996) Can biochemical markers predict bone loss at the hip and spine?: a 4-year prospective study of 141 early postmenopausal women. Osteoporos Int 6:399–406PubMedCrossRefGoogle Scholar
  59. 59.
    Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055PubMedCrossRefGoogle Scholar
  60. 60.
    Khosla S, Arrighi HM, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Dunstan C, Riggs, BL(2002) Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394–399PubMedCrossRefGoogle Scholar
  61. 61.
    Krall EA, Dawson-Hughes B, Hirst K, Gallagher JC, Sherman SS, Dalsky G (1997) Bone mineral density and biochemical markers of bone turnover in healthy elderly men and women. J Gerontol A Biol Sci Med Sci 52:M61–M67PubMedGoogle Scholar
  62. 62.
    Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566–1571PubMedCrossRefGoogle Scholar
  63. 63.
    Lindsay R, Hart DM, Forrest C, Baird C (1980) Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151–1154PubMedCrossRefGoogle Scholar
  64. 64.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2005) Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 16:372–379PubMedCrossRefGoogle Scholar
  65. 65.
    Lofman O, Magnusson P, Toss G, Larsson L (2005) Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. Clin Chim Acta 356:75–76CrossRefGoogle Scholar
  66. 66.
    Lormeau C, Soudan B, d’Herbomez M, Pigny P, Duquesnoy B, Cortet B (2004) Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone 34:933–939PubMedCrossRefGoogle Scholar
  67. 67.
    Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 20:579–587PubMedCrossRefGoogle Scholar
  68. 68.
    Melton LJ 3rd, Khosla S, Atkinson EJ, O’Fallon WM, Riggs B (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091PubMedCrossRefGoogle Scholar
  69. 69.
    Metra Biosystem, Metra®CICP and Metra®DPD (2006), Performance of the test
  70. 70.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRefGoogle Scholar
  71. 71.
    Miller PD, Siris ES, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Chen YT, Berger ML, Santora AC, Sherwood LM (2002) Prediction of fracture risk in postmenopausal women white women with peripheral bone densitometry: Evidence from the national osteoporosis risk assessment. J Bone Miner Res 17:2222–2230PubMedCrossRefGoogle Scholar
  72. 72.
    Monaghan DA, Power MJ, Fottrell PF (1993) Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. Clin Chem 39:942–947PubMedGoogle Scholar
  73. 73.
    Morii H, Ohashi Y, Taketani Y, Funkunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793–800PubMedCrossRefGoogle Scholar
  74. 74.
    Nakasato YR, Janckila AJ, Halleen JM, Vaananen HK, Walton SP, Yam LT (1999) Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 45:2150–2157PubMedGoogle Scholar
  75. 75.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRefGoogle Scholar
  76. 76.
    Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812CrossRefGoogle Scholar
  77. 77.
    Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K, Teisner B (1996) Procollagen type I N-terminal propetide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 19:157–163PubMedCrossRefGoogle Scholar
  78. 78.
    Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K (2005) Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study: a large observational study of the determinants of fracture in older men. Contemp Clin Trials 26:569–585PubMedCrossRefGoogle Scholar
  79. 79.
    Parviainen M, Kuronen I, Kokko H, Lakaniemi M, Savolainen K, Mononen I (1994) Two-site immunoassay for measuring intact human osteocalcin in serum. J Bone Miner Res 9:347–354PubMedGoogle Scholar
  80. 80.
    Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRefGoogle Scholar
  81. 81.
    Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRefGoogle Scholar
  82. 82.
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRefGoogle Scholar
  83. 83.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, EthgenD, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
  84. 84.
    Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J (2005) Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women, results from the monthly oral pilot study. J Clin Endocrinol Metab 90:5018–5024PubMedCrossRefGoogle Scholar
  85. 85.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier P (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRefGoogle Scholar
  86. 86.
    Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635–640PubMedGoogle Scholar
  87. 87.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE (2005) Treatments with once-weekly risendronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151PubMedCrossRefGoogle Scholar
  88. 88.
    Rosenquist C, Bonde M, Fledelius C, Qvist P (1994) A simple enzyme-linked immunosorbent assay of human osteocalcin. Clin Chem 40:1258–1264PubMedGoogle Scholar
  89. 89.
    Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J (2000) Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–373PubMedCrossRefGoogle Scholar
  90. 90.
    Seeman E, Eisman JA (2004) 7: treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual’s absolute risk of fracture. Med J Aust 15 180:298–303PubMedGoogle Scholar
  91. 91.
    Schaller S, Henriksen K, Sveigaard C, Heegard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal M (2004) The chloride channel inhibitor N53736 prevents bone resorption ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144–1153PubMedCrossRefGoogle Scholar
  92. 92.
    Schaller S, Henriksen K, Hoegh-Andersen P, Søndergaard BC, Sumer EU, Tanko LB, Qvist P, Karsdal M (2005) In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint disease: how biomarkers can assist? Assay Drug Dev Technol 3:553–580PubMedCrossRefGoogle Scholar
  93. 93.
    Schuit SC, Van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, Van Leeuwen JP, Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRefGoogle Scholar
  94. 94.
    Schlemmer A, Hassager C, Alexandersen P, Fledelius C, Pedersen BJ, Kristensen IO, Christiansen C (1997) Circadian variation in bone resorption is not related to serum cortisol. Bone 21:83–88PubMedCrossRefGoogle Scholar
  95. 95.
    Sclemmer A, Hassager C (1999) Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140:332–337CrossRefGoogle Scholar
  96. 96.
    Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas P (2005) Identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Min Res 20:1813–1819CrossRefGoogle Scholar
  97. 97.
    Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK (1992) Age-related decrements in bone mineral density in women over 65. J Bone Miner Res 7:625–632PubMedCrossRefGoogle Scholar
  98. 98.
    Stephan JJ (2000) Prediction of bone loss in postmenopausal women. Osteo Int (Suppl 6):S45–S54Google Scholar
  99. 99.
    Tanko LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687–693PubMedCrossRefGoogle Scholar
  100. 100.
    Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649PubMedCrossRefGoogle Scholar
  101. 101.
    Warming L, Ravn P, Spielman D, Delmas P, Christiansen C (2004) Trimegestone in a low-dose, continous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 11:337–342PubMedCrossRefGoogle Scholar
  102. 102.
    Watts NB (1999) Clinical utility of biochemical markers of bone remodeling. Clin Chem 45:1359–1368PubMedGoogle Scholar
  103. 103.
    Woo J, Lau E, Swaminathan R, Pang CP, MacDonald D (1990) Biochemical predictors for osteoporotic fractures in elderly Chinese—a longitudinal study. Gerontology 36:55–58PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • D. J. Leeming
    • 1
  • P. Alexandersen
    • 2
  • M. A. Karsdal
    • 3
  • P. Qvist
    • 1
  • S. Schaller
    • 3
  • L. B. Tankó
    • 2
  1. 1.Nordic Bioscience Diagnostics A/SHerlevDenmark
  2. 2.Center for Clinical and Basic Research A/SBallerupDenmark
  3. 3.Pharmos Bioscience A/SHerlevDenmark

Personalised recommendations